陈红敏院士是美国工程院、美国医学和生物工程研究所、控释协会以及德克萨斯大学奥斯汀分校杰出化学工程师学院的成员。她获得了德州大学奥斯汀分校化学工程学士学位及麻省理工学院化学工程专业硕士学位、科学博士学位。

加入剂泰医药之前，陈红敏院士曾担任Kala制药的首席科学官，该生物技术公司由其于2010年协助创立。就职期间，她成功将一项新型纳米颗粒技术从实验发现阶段推进至三期临床试验阶段，并获得FDA批准。陈红敏院士帮助公司吸引了大量投资并协助Kala制药于2017年在纳斯达克上市。在加入Kala制药之前，陈红敏院士协助创立了TransForm制药，该医药公司于2005年被美国强生收购。除此之外，她还曾在阿斯利康和默克担任过多种研发岗位。

She is a member of the National Academy of Engineering, a Fellow of the American Institute for Medical and Biological Engineering, a Fellow of the Controlled Release Society and a member of the Academy of Distinguished Chemical Engineers at the University of Texas at Austin. Dr. Chen holds a B.S. in Chemical Engineering from UT Austin and an M.S. and an Sc.D. in Chemical Engineering from Massachusetts Institute of Technology. 

Before joining METiS, Dr. Chen served as Chief Scientific Officer at Kala Pharmaceuticals, a biotech company she helped found in 2010. At Kala, she successfully translated a novel nanoparticle technology from bench to Phase III clinical trials and FDA approval, and helped to attract significant investments to the company, including an initial public offering in 2017.  Prior to Kala, Dr. Chen helped start and build TransForm Pharmaceuticals, which was acquired by Johnson & Johnson in 2005. She had also held various research positions at AstraZeneca and Merck. 